Inogatran

CAS : 155415-08-0

Ref. 3D-FGA41508

Informations sur le produit

• Nom: Inogatran
• Synonymes: Glycine, N-[2-[2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]-, [S-(R*,S*)]-, N-[(1R)-2-[(2S)-2-[[[3-[(Aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]glycine, N-[(2R)-1-{(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl}-3-cyclohexyl-1-oxopropan-2-yl]glycine, glycine, N-[(1R)-2-[(2S)-2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]-

Description

Inogatran is a potent and selective inhibitor of the enzyme, activated C5a anaphylatoxin chemokine (C5a-AC) that is involved in the inflammatory response to tissue injury. Inogatran has been shown to inhibit the binding of C5a-AC to its receptor on neutrophils, macrophages, and eosinophils. The anti-platelet activity of inogatran is due to its ability to inhibit C5a-AC mediated platelet activation and aggregation. Inogatran also inhibits the release of tumor necrosis factor alpha (TNFα) from macrophages and inhibition of TNFα release suppresses tumour growth in vivo. In addition, inogatran significantly reduces melanoma growth by inhibiting the expression of melanoma antigen (MART-1).

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 438.6 g/mol
• Formule: C₂₁H₃₈N₆O₄
• Degré de pureté: Min. 95%